Apr 16, 2025, 15:03 | Insight

Richard Sullivan: The 2025 model lists of essential medicines for cancer

Richard Sullivan, Director of the Institute of Cancer Policy and Co-Director of the Centre for…

Apr 10, 2025, 11:14 | Science

Richard Sullivan: What is the role for China reshaping Global Health for a low-cooperation world?

Richard Sullivan, Professor of Cancer and Global Health at King’s College London, shared an article…

Apr 8, 2025, 07:09 | Blog

EACR - Registration is open for Defence is the Best Attack: Immuno-Oncology Breakthroughs Conference

European Association for Cancer Research (EACR) posted on LinkedIn: "You have one week left to…

Mar 1, 2025, 09:12 | Blog

Stefan Alig: The Alig Lab is hiring

Stefan Alig, Clinician Scientist, Department of Hematology and Stem Cell Transplantation at University Hospital Essen,…

Feb 28, 2025, 15:12 | Blog

Catherine Alix-Panabières: Honored to welcome Key International Experts in Liquid Biopsy from 14 different countries

Catherine Alix-Panabières, Professor of Oncology at the Faculty of Medicine of the University of Montpellier,…

Feb 27, 2025, 08:25 | Blog

Antonio Passaro: I had the opportunity to participate in the Immuno Oncology South Africa

Antonio Passaro, Medical oncologist at the European Institute of Oncology in Milan, shared a post…

Feb 25, 2025, 13:38 | Blog

Sean Burroughs: 2025 Funding Rounds and Growing Therapeutic Trends

Sean Burroughs, President & Co-Founder at Thorough Group, shared a post on LinkedIn: "I know…

Jan 25, 2025, 05:06 | Blog

Danielle Pastor Leads Clinical Trial on ANK-101 Immunotherapy - NCI Center for Cancer Research

NCI Center for Cancer Research shared a post on LinkedIn: "Now Enrolling: Danielle Pastor, D.O.,…

Jan 16, 2025, 10:01 | Blog

Narjust Florez and Alfredo Addeo dive into the data from ESMO - IASLC

The International Association for the Study of Lung Cancer shared a post on X: "New…

Dec 21, 2024, 10:35 | Insight

30 Years of Leadership in Immuno-Oncology - Agenus

Agenus shared on LinkedIn: “For 30 years, we have been at the forefront of immuno-oncology.…

Dec 21, 2024, 10:09 | Dialogues

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Interview with Mikhail Groubman, By the Editor-in-Chief of OncoDaily, Gevorg Tamamyan Mikhail Groubman is the…

Dec 20, 2024, 22:35 | Blog

Jennifer S. Buell: Transforming cancer care through innovation in immuno-oncology

Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, posted the following on…

Nov 9, 2024, 20:04 | Blog

Toni Choueiri on the Flexibility of Therapies Beyond PD-1 Inhibitors

Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, shared…

Nov 2, 2024, 19:05 | Insight

Deridre Kelly: Anti–PD-L1 and TKI in anaplastic thyroid cancer

Deridre Kelly, Medical Oncologist at Mater Misericordiae University Hospital, shared a post on X: "Immuno…

Oct 29, 2024, 21:00 | Positive

Steven O'Day: At the Forefront of Immunotherapy

Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…

Oct 14, 2024, 14:37 | Blog

Society for Immunotherapy of Cancer - Experience the latest in Immuno Oncology science at SITC 2024

Society for Immunotherapy of Cancer shared on X: '' Experience the latest in Immuno Oncology…

Oct 9, 2024, 07:58 | Blog

Last chance to register for ESMO Immuno 24 in Geneva - ESMO

ESMO - European Society for Medical Oncology posted the following on LinkedIn: “ESMO Immuno 24:…

Oct 3, 2024, 07:42 | Societies

The early registration deadline for ESMO Immuno24 is fast approaching

ESMO shared on LinkedIn: "ESMO Immuno24: The early registration deadline is fast approaching! Connect with…

Sep 28, 2024, 06:59 | Blog

Shubh Goel: AstraZeneca’s ambition in oncology aims for a future where cancer is no longer a cause of death

Shubh Goel, VP and US Franchise Head, Immuno-Oncology and GI Tumors at AstraZeneca, shared a post…

Sep 2, 2024, 08:40 | Blog

David Braun: We can make a personalized vaccine to target those tumor-specific antigens

Dana-Farber Cancer Institute shared a post on X: “'If we can identify neoantigens specific to…

Aug 25, 2024, 12:48 | Blog

The development of multimodal AI for clinical decision making in immunotherapy - NCI Systems Biology

NCI Systems Biology shared a post on X: "On Aug. 29 at 2:30 pm ET, Anant…

Aug 10, 2024, 19:12 | Societies

Register for the SITC Immuno-oncology Drug Development Summit in Boston

Society for Immunotherapy of Cancer (SITC) shared on X: "Register for the SITC Immuno-oncology Drug…

Aug 5, 2024, 15:54 | Career

Shivan Sivakumar: I am celebrating being at University of Birmingham for a year

Shivan Sivakumar, Associate Professor in oncology at the University of Birmingham, shared on X: "This…

Aug 3, 2024, 03:01 | Blog

Belén Garijo on Q2 results from Merck

Belén Garijo shared a post on LinkedIn: "We published our Q2 results today! Earlier this…

Jul 31, 2024, 09:17 | Blog

New Lung Cancer Considered episode, the use of ICIs in the treatment of molecular driven NSCLC

IASLC shared on X: "In this Lung Cancer Considered episode, Narjust Florez and 2 esteemed…

Jul 28, 2024, 08:50 | Insight

Novartis collaborates with Dren Bio to discover and advance novel antibody-based immune cell engagers

Fiona Hamilton Marshall, President of the Novartis Institute for BioMedical Research, shared on LinkedIn: “I’m…

Jul 26, 2024, 14:16 | Blog

2024 Multi-omics Meeting in Australia - Society for Immunotherapy of Cancer

Society for Immunotherapy of Cancer (SITC) shared a post on X: "Connect with global researchers…

Jul 19, 2024, 14:44 | Blog

"What’s Next for Immunotherapies?" by Anas Younes

Anas Younes shared a post on LinkedIn: Immunotherapies Immunotherapies "My interview with Mark Cobbold, Senior…

Jul 19, 2024, 02:00 | Blog

I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan

"~20% ORR and 90% alive at 6 months in comparison to ZERO! How many patients…

Jul 18, 2024, 15:20 | Drugs

Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO

Agenus shared on LinkedIn: "Today, we announced the outcomes of our End-of-Phase 2 meeting and…

Jul 14, 2024, 21:15 | Blog

Sumanta K. Pal: Excellent use of Twitter polls to reconcile tough clinical scenarios

Sumanta K. Pal shared a post on X: ''Brilliant insights from Tom Powles, Barts Cancer Institute.…

Jul 14, 2024, 07:19 | Insight

Immuno-oncologic profiling of pediatric brain - Hawkins Lab

Hawkins Lab shared a recent paper on X, titled "Immuno-oncologic profiling of pediatric brain tumors reveals…

Jul 10, 2024, 05:18 | Insight

APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million

APEIRON Biologics AG (“APEIRON”), a leading Austrian biotech company, today announced that its shareholders have…

Jul 7, 2024, 17:43 | Insight

Jarushka Naidoo: ctDNA+ associates with outcomes in stage III unresectable NSCLC

Jarushka Naidoo shared a post on X: “ctDNA+ in consolidation IO trial (BTCRC 16-081) associates…

Jun 27, 2024, 12:44 | Societies

Discuss the future of immuno-oncology with Agenus at ESMOGI24

Agenus shared on LinkedIn: "If you are a physician attending ESMOGI24 in Munich from June…

Jun 27, 2024, 09:10 | Insight

The promise of immuno-oncology in the neoadjuvant setting - ESMO

The European Society for Medical Oncology (ESMO) shared on LinkedIn: “The promise of immuno-oncology in…

Jun 18, 2024, 23:25 | Insight

The future of immuno-oncology discussion with Agenus at ESMO GI 2024

Agenus shared a post on LinkedIn: “Are you a physician attending ESMO GI 24? Join…

Jun 11, 2024, 15:17 | Blog

Julian Ashby: Deep preclinical characterization is essential to increase the chances of success in clinical trials

Julian Ashby, Product Marketing Manager at LUMICKS, shared on LinkedIn: “Each year, companies use tens…

Jun 4, 2024, 05:09 | Insight

Join us in Chicago to discuss the future of immuno-oncology - Agenus

Agenus shared a post on LinkedIn: “Are you a physician attending ASCO24? Join us in…

May 1, 2024, 13:27 | Blog

Jennifer Marks: Reconsideration of IO in the inpatient setting

Jennifer Marks, Hematologist, Oncologist at MedStar Georgetown University Hospital, shared on X/Twitter: "Poster presentation on reconsideration…

Apr 23, 2024, 23:33 | Insight

Narjust Florez: Jessica Donington dissects adjuvant Immuno-Oncology in lung cancer

Narjust Florez shared a post on X: “Jessica Donington dissects adjuvant Immuno-Oncology in lung cancer.…

Apr 22, 2024, 10:32 | Blog

Narjust Florez: Dr. Julia Rotow discussed the role of IO in patients with target mutations

Narjust Florez shared a post on X: "IO and target therapy? Dr. Julia Rotow discussed…

Apr 19, 2024, 05:17 | Insight

Dina Schneider: Excited about our recent publication on Armored TGFBRIIdn ROR1-targeting CAR T cells for solid tumors

Dina Schneider, Director of Immuno Oncology and Cell Therapy at Lentigen Technology, shared on LinkedIn:…

Apr 4, 2024, 14:40 | Career

Nick Slack: I'm excited and humbled to announce my new role as Chairman and CEO of The START Center for Cancer Research

Nick Slack, Chairman and CEO of The START Centre for Cancer Research, shared on LinkedIn:…

Mar 28, 2024, 03:20 | Blog

Roberto Iacovelli: Thrilled to announce that TIDE-A trial is finally out on European Urology

Roberto Iacovelli, Associate Professor of Medical Oncology at Sacro Cuore Catholic University of Rome, shared on…

Mar 24, 2024, 13:47 | Career

Jean-Charles Soria: Thank you to my American Association for Cancer Research colleagues for this humbling vote of confidence

Jean-Charles Soria, SVP and Oncology Therapeutic Area Head, shared Amgen Oncology's post on LinkedIn and…

Jan 18, 2024, 15:12 | Blog

Maria Natalia Gandur Quiroga: Immuno-Oncology Advances in Genitourinary Cancers

Maria Natalia Gandur Quiroga shared a post on LinkedIn: "Immuno-Oncology Advances in Genitourinary Cancers: Introduction:…

Jan 9, 2024, 09:37 | Blog

“The Immuno-Oncology Curve” with Dr. Steven O’Day – Guests are Alexa Morell, Marianne Pearson and Andrew Wortmann

Steven O’Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "Happy New Year! I’m…

Dec 18, 2023, 21:17 | Insight

Anthony Zamora: How advancements in sequencing technologies and bioinformatics pipelines have advanced our ability to identify cancer neoantigens

Anthony Zamora, Assistant Professor at the Medical College of Wisconsin, announced on LinkedIn: "Happy to…

Nov 28, 2023, 16:14 | Blog

“The Immuno-Oncology Curve" with Dr. Steven O'Day - Guest is Alexander (Lex) Eggermont

Steven O'Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "I’m excited to announce…

Nov 20, 2023, 10:30 | Insight

Steven O'Day: I am thrilled to announce the upcoming launch of “The Immuno-Oncology Curve”

Steven O'Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "I am thrilled to…

Nov 17, 2023, 16:24 | Drugs

Caroline J Loew: We’re excited to launch Mural Oncology

Caroline J Loew, CEO of Mural Oncology, shared Mural Oncology's post on LinkedIn adding: "We’re…

Nov 17, 2023, 13:59 | Insight

Revolutionizing Cancer Immunotherapy: Next-Gen CTLA-4 Targeting and Combination Therapies

Dive into the groundbreaking research published in "Oncology Immunology" (2023), where leading scientists Nils-Petter Rudqvist,…

Sep 24, 2023, 18:03 | Blog

Pashtoon Murtaza Kasi: The imagery at RareCyte Incorporated will blow your mind.

Quoting Pashtoon Murtaza Kasi, Oncologist and Researcher at Weill Cornel Medicine and New York- Presbyterian…

Sep 22, 2023, 17:54 | Blog

Together, we're shaping the future of healthcare! - IMAGIO Project

Quoting IMAGIO Project on LinkedIn: "The IMAGIO Consortium is composed by top experts in the…

Sep 12, 2023, 18:48 | Blog

Eric Deutsch: The countdown begins as ImmunoRad2023 7th edition fast approaches.

Quoting Eric Deutsch, Head of the Gustave Roussy Radiotherapy Department, on LinkedIn: ''The countdown begins as…

Aug 22, 2023, 18:09 | Career

Beatrice Duvert: I’m happy to share that I’m starting a new position as an Associate Program Manager at Agenus!

Quoting Beatrice Duvert, Associate Program Manager at Agenus, on LinkedIn: "I’m happy to share that…